The VENAZA-5S pilot trial is exploring a modified treatment regimen of Venetoclax in combination with a reduced duration of Azacitidine for treatment-naïve patients with Acute Myeloid Leukemia (AML) who are ineligible for standard induction therapy. This study aims to enhance tolerability and adherence, potentially leading to improved patient outcomes and quality of life. The market for AML therapies is growing, driven by the increasing incidence of the disease and the need for effective treatments for elderly and comorbid patients. AbbVie’s involvement as a collaborator indicates strategic interest in expanding the Venetoclax portfolio, which could enhance competitive positioning against other therapies in the AML space. The results of this trial may provide critical data to support further development and commercialization strategies, particularly in Europe where the standard of care is evolving.